This study will determine reference genomic, transcriptomic, proteomic and metabolomic profiles in Czech population and will evaluate its correlation with the disease phenotype.
age 18 - 68 years
healthy volunteers without genetically dependent disease and without such a disease in a family
healthy volunteer without the preliminary evidence of civilizational diseases such as hypertension, diabetes, autoimmune and tumor diseases or acute infectional diseases; clinically manifesting cardiovascular or pulmonary disability.
subject without permanent of long-term medication in the time of biological sampling.
not complying with inclusion criteria
Selection from the blood donnors from the blood transfusion department.
Other
Prospective
Blood sample analysis
GeneticNucleic acids sequencing, presence of proteins and metabolites.
Health status
Other interventionHealth status will be examined by a physician and subject will complete a health status questionnaire.
Race and ethnicity
Other interventionSubject will complete race and ethnicity questionnaire to make sure subjects are from the Czech population.
Whole Genome (Exom) Sequencing of the Healthy Volunteers - establishment of the HEALTHY VOLUNTEER REFERENCE GENOME (min. 1000 individuals)
Establishment of the Healthy Volunteers Whole Genome (Exom) Reference Database typical for the population of the Czech Republic/Central Europe.
Whole Genome (Exom) Sequencing of the patient groups with different diseases and their comparison to the HEALTHY VOLUNTEER REFERENCE GENOME
Whole Genome (Exom) Sequencing of the patient populations presenting various diseases. Based on the comparison with the HEALTHY VOLUNTEER REFERENCE GENOME - determination of various genetic polymorphisms (single nucleotide polymorphisms, insertions, deletions, inversions, copy-number variations etc.) and giving these into correlation with disease phenotypes.
Evaluation of the correlation with the disease phenotype
Based on the reference database of healthy volunteers in the Czech Republic a potential correlations will be evaluated among genomic, proteomic and metabolomic profiles of patients and the disease phenotypes.
Click on the lead sponsor to view all of their trials.
